Premium
Association Between Staphylococcus aureus Bacteremia and Hospital Mortality in Hemodialysis Patients With Bloodstream Infection: A Multicenter Cohort From Japanese Tertiary Care Centers
Author(s) -
Imaizumi Takahiro,
Hasegawa Takeshi,
Nomura Atsushi,
Sasaki Sho,
Nishiwaki Hiroki,
Ozeki Takaya,
Shimizu Hideaki,
Minatoguchi Shun,
Yamakawa Taishi,
Yazawa Masahiko,
Uchida Daisuke,
Kawarazaki Hiroo,
Miyamoto Masahito,
Suzuki Tomo,
Koitabashi Ken'ichiro,
Furusho Masahide,
Fujita Yoshiro
Publication year - 2017
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/1744-9987.12534
Subject(s) - medicine , bacteremia , hemodialysis , staphylococcus aureus , cohort , retrospective cohort study , cohort study , intensive care medicine , antibiotics , microbiology and biotechnology , genetics , bacteria , biology
Multiple studies have shown that Staphylococcus aureus bacteremia (SAB) has been a major cause of death in hemodialysis patients. We examined whether SAB is a risk for mortality among chronic hemodialysis patients in Japan where the standard vascular access is arteriovenous fistula (AVF). This was a multicenter, retrospective study of maintenance hemodialysis patients with bloodstream infection (BSI) from 2011 to 2013 at tertiary care centers in Japan. The endpoint was hospital mortality. Our cohort contained 32 SAB cases (14 MRSA and 18 MSSA) and 42 non‐SAB cases. Hospital mortality was higher among SAB cases than non‐SAB cases (46.9% vs. 23.8%, P = 0.038). In patients with BSI, SAB was significantly associated with hospital mortality after adjustment for potential confounders, including type of vascular access (OR 3.26). S. aureus was the leading cause of BSI and hospital mortality among this cohort. Therefore, initial empiric treatment should cover for S. aureus .